BMY vs ZBIO
BMY: A leading biopharmaceutical innovator focused on discovering and delivering life-changing medicines to address serious illnesses globally. ZBIO: Clinical-stage immunology company developing obexelimab, a novel bifunctional monoclonal antibody targeting B cells for the treatment of autoimmune diseases.
Side-by-side fundamentals
| Metric | BMY | ZBIO | Edge |
|---|---|---|---|
| Price as of 2026-08-21 close | $67.01 | $32.29 | |
| Market cap as of 2026-08-24 | $136.9B | $2.1B | |
| P/E as of 2026-08-24 | 14.21 | n/a | |
| PEG as of 2026-08-24 | -8.67 | -0.10 | BMY lower |
| Net margin as of 2026-08-24 | +18.9% | -3777.4% | BMY higher |
| Gross margin as of 2026-08-24 | +71.7% | n/a | |
| Operating margin as of 2026-08-24 | +25.5% | -3830.6% | BMY higher |
| ROE as of 2026-08-24 | +46.8% | -167.7% | BMY higher |
| ROA as of 2026-08-24 | +10.3% | -97.4% | BMY higher |
| Debt / equity as of 2026-08-24 | 1.93 | 1.04 | ZBIO lower |
| Revenue growth (YoY) as of 2026-08-24 | +3.1% | n/a | |
| Revenue CAGR (3y) SEC XBRL | +1.4% | -55.3% | BMY higher |
| Dividend yield as of 2026-08-24 | +4.6% | n/a | |
| Dividend streak (yrs) SEC XBRL | 5 | n/a | |
| Beta as of 2026-08-24 | 0.18 | 0.70 | |
| 1-year return as of 2026-08-21 close | +38.4% | +90.7% | ZBIO higher |
Fundamentals: market data, as of 2026-08-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.